Can a common diabetes drug protect the heart? new trial aims to find out
NCT ID NCT07288749
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 3 trial will test whether glimepiride, a standard diabetes pill, can reduce the risk of heart-related death, heart transplant, or worsening heart failure in people with type 2 diabetes and chronic heart failure. About 1,484 participants will receive either glimepiride or a placebo, alongside standard treatments for both conditions. The study aims to see if adding glimepiride improves outcomes over standard care alone.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
glimepiride (oral diabetes medication)
What this could lead to
If successful, this could show that glimepiride safely helps manage both diabetes and heart failure, reducing the risk of death or hospitalization.
What could go wrong
This is a large Phase 3 trial, but glimepiride is an older drug and may not outperform placebo in this specific heart failure population. Results may not apply outside China.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES MELLITUS (T2DM) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Tongji Hostipal
Wuhan, Hubei, 430030, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••